Sangamo Biosciences (SGMO) has disclosed a new risk, in the Manufacturing category.
Sangamo Biosciences, as a biopharmaceutical company, does not engage in mining or related activities; therefore, Item 4 regarding mine safety disclosures does not apply to their operations. This exclusion indicates that Sangamo does not face the stringent regulatory compliance and potential risks associated with mine safety. Investors should note that the company’s risk factors are more aligned with clinical development, regulatory approvals, and intellectual property protection rather than issues pertaining to mining. The absence of this risk signifies a more focused assessment of Sangamo’s unique industry challenges.
The average SGMO stock price target is $2.60, implying 363.13% upside potential.
To learn more about Sangamo Biosciences’ risk factors, click here.
